MoneyMaestro

DNAPrint Pharmaceuticals / Harvard Study Shows PT-401 to Be Three Times More Potent Than Conventional EPOs in Treating Anemia
Friday December 8, 7:00 am ET

"Important Therapeutic Advantages" Are Suggested; Results to Be Released at American Society of Hematology Annual Meeting

SARASOTA, FL--(MARKET WIRE)--Dec 8, 2006 -- DNAPrint Genomics, Inc. (OTC BBNAG.OB - News) today announced the results of preclinical studies conducted by the Company and Harvard Medical School on the Company's proprietary PT-401 protein. The studies demonstrate that PT-401 is three times more effective than conventional EPO treatments, and conclude that PT-401 has "biological activities superior to those of EPO monomer, suggesting important therapeutic advantages."

ADVERTISEMENT
The results of the study will be formally presented by Drs. Jee-Yeong Jeong and Arthur J. Sytkowski on Dec. 9, 2006, at the American Society of Hematology 48th Annual Meeting and Exposition in Orlando, Fla. Dr. Sytkowski is the Director of the Laboratory for Cell and Molecular Biology at Beth Israel Deaconess Medical Center (BIDMC), an affiliate of Harvard Medical School.

The study's purpose was to determine whether it was possible to develop a more effective erythropoiesis stimulating agent (ESA) than human erythropoietin (EPO, epoetin), which is widely used in the treatment of certain forms of anemia but which has a relatively short in vivo half-life, resulting in considerably high and frequent doses in order to maintain therapeutic effectiveness. The study, conducted over a seven day period using laboratory mice, showed that the "super EPO" that forms the basis for PT-401, and which comprises EPO-dimer and EPO-trimer fusion proteins that were comprised of "head-to-tail" repeats, is up to three times more effective than conventional EPO treatments, exhibiting enhanced biological properties in vitro and in vivo.

"Dr. Sytkowski is one of the foremost scientists in the field of therapeutic protein research, particularly Erythropoietin," stated DNAPrint Chairman and Chief Medical Officer Hector J. Gomez, M.D., Ph.D. "We are proud that our affiliation with Dr. Sytkowski and Beth Israel Deaconess Medical Center has produced this research, which shows the promise of PT-401 in treating chronic anemia due to renal failure, cancer, or other causes."

"This study is an important step in the advancement of PT-401 as a potential competitor in the EPO market, which currently exceeds $10 billion and is rapidly growing," stated DNAPrint Genomics President and Chief Executive Officer Richard J. Gabriel. "This study is just one step, however, and we look forward to continuing our collaboration with Dr. Sytkowski as this project advances."

PT-401 is a "Super EPO," a more powerful erythropoiesis stimulating agent than Erythropoietin, a well-known drug used for the treatment of anemia. Previously, DNAPrint Pharmaceuticals, the Company's wholly owned subsidiary, announced three successful milestones related to PT-401: the use of CHO cell lines, the use of SDS-PAGE, a well-established separation technique for the testing of cell lines, and a specially developed isoelectric focusing (IEF) method. The initial research has been conducted in conjunction with Dr. Sytkowski.

In addition to Dr. Sytkowski, research was carried out with Drs. Jee-Yeong Jeong, Changmin Chen and Kerry L. Davis of the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at the Beth Israel Deaconess Medical Center and Department of Medicine, Harvard Medical School.

The study was conducted in conjunction with the UCLA Olympic Analytical Laboratory in the Department of Molecular and Medical Pharmacology at the University of California at Los Angeles and included Drs. Andreas Breidbach and Don H. Caitin.

The study and its results are illustrated in a multi-color poster that Dr. Sytkowski will distribute as part of the presentation.

About Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit Beth Israel Deaconess Medical Center, Boston.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (DNA Print genomics) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to DNA Print genomics for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Contact:

Company Contact:
Richard Gabriel
CEO and President
941 366-3400

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848


Source: DNAPrint Genomics, Inc.

__________________
Use the Best Tools to make the Best Trades! Learn How (Click Here)

Microcap Feed: Get your 30 day FREE TRIAL

seminoles20

nice call

rider3160

one to watch for monday

__________________
Clickity clank
Clickity clank
The money goes in to my piggy, bank

mammamia13

Genetic Marker for Statin-Induced Myalgia

M2 "Press Wire "

M2 PressWIRE - December 19, 2006 - DNAPrint Genomics, Inc. (OTC BB: DNAG) operates as a developer of genomics-based products and services primarily in biomedical and forensics markets in the United States. For more information visit DNA Print genomics.

Shares are up 38% on a volume of over 14 million in the morning trading. Today's momentum came in as DNAPrint Genomics, Inc. (OTC BB: DNAG), announced that the Company's research staff has discovered a genetic marker for statin-induced myalgia (chronic muscle pain), that a patent has been filed to protect the discovery and that the research on which the discovery is based will be published in an upcoming issue of The Journal of Pharmacogenetics and Genomics (JPG).

MarketGainer.com is quickly emerging as one of the newest and most exciting online newsletters for international, small-cap investors looking to stay a step ahead of the markets.

The marker was the primary discovery from the Company's Statnome project initiated in 2000 and the manuscript to be published in JPG describes the validation of this finding in different patient samples.

"Myalgia or chronic muscle pain is a common side effect reported by patients who take statins for cholesterol control, and it is likely to be part of a disease continuum that includes myositis and rhabdomyolysis, which is a breakdown of muscle fibers that frequently results in kidney damage and is a potentially fatal side-effect," according to DNAPrint Chief Science Officer Tony Frudakis, Ph.D. "Deaths associated with statin-induced rhabdoymyolysis lead Bayer to withdraw Cerivistatin in 2001. We are satisfied to have brought one of our first pharmacogenetics programs full circle from discovery through validation and we consider the R&D phase for this project complete. With the filing of a patent to protect this discovery, the Company will be able to develop a proprietary test for this gene variant and thereby reduce the likelihood of illness or death in those patients who are taking statins. This study also criticizes the original clinical trials for statins, which did not fully or adequately explore the relationship between statins and myalgia or even rhabdomyolysis."

"This is the culmination of a project that was begun when the company was founded," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It has taken until now to validate the original findings, but validated they are. The Company has filed a patent to protect this process. We plan to bring to market a definitive test product to identify this genetic variant and to potentially prevent painful -- and in some cases, fatal -- side effects in thousands of patients who are taking a very common prescription drug."

DNAPrint's study of 750 patients who had taken either atorvastatin (Lipitor ) or simvastatin (Zocor ) showed that patients carrying one specific genetic marker were approximately 2.5 times more likely to experience mild to severe muscle pain (myalgia). The effect was most pronounced for atorvastatin and the study showed that approximately one half of the patients who were removed from atorvastatin therapy due to muscle symptoms possess this genetic marker, whereas in the general population (with and without cardiovascular disease) only approximately 15%-25% of people carry the marker. DNAPrint applied its technology for measuring population structure (e.g., ancestry) in order to prove that the finding in both the discovery and validation samples was genuine, and in so doing received praise from JPG reviewers. This observation indicates that the genetic marker may be related not only to response to statins but also to a possible relationship with higher cholesterol levels, according to the study.

"DNA Print Genomics was founded on the underlying genomic screening methods developed to more efficiently scan the genome for medically important genetic markers of drug responses," stated Dr. Frudakis. "The current findings are another example of the efficiency of the Company's methods."

DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to DNA Print genomics for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

To view the rest of today's articles and comparables join us at Marketgainer.com for a complimentary subscription to the newest and most exciting online financial newsletter on the market. This article is available for viewing in the featured articles section on our website. No Credit Card information needed.

The Financial Information and Financial Content provided by Marketgainer.com is for informational purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or endorsement, recommendations, or sponsorship of any company or security by Marketgainer.com. You acknowledge and agree that any request for information is unsolicited and shall neither constitute nor be construed as investment advice by Marketgainer.com to you. It is strongly recommended that you seek outside advice from a qualified securities professional prior to making any securities investment. Marketgainer.com does not provide or guarantee any legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or informational source.

All material herein was prepared by based upon information believed to be reliable. The information contained herein is not guaranteed by Market Gainer to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Market Gainer is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

((Comments on this story may be sent to info@m2.com))

© 2006 M2 COMMUNICATIONS LTD

rider3160

gapping on news

__________________
Clickity clank
Clickity clank
The money goes in to my piggy, bank